Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

consumer health

  • Home
  •  
  • consumer health



  • Most Read
  • Latest Comments
  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • EVE Targets Expansion in Global Pharma Markets Following $0.9m Raise
    EVE Targets Expansion in Global Pharma Markets Following $0.9m Raise
    • News

  • ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    • News

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

  • Melodiol moves to clear debt with $12m asset fire sale
    Melodiol moves to clear debt with $12m asset fire sale
    • News

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies

    Pharmaceutical and consumer health company, Bioxyne (ASX: BXN) has become the first manufacturer in Australia to produce cannabis gummies under a Good Manufacturing Practice (GMP) licence. Through its subsidiary, Breathe Life Sciences (BLS), Bioxyne has completed the first commercial run of these pharmaceutical-grade edibles, taking an early position in Australia’s fast-evolving medicinal cannabis market where

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.